Scienture Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCNX research report →
Price Chart
About the company
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.
- CEO
- Shankar Hariharan
- IPO
- 2014
- Employees
- 9
- HQ
- Commack, NY, US
Get TickerSpark's AI analysis on SCNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.11M
- P/E
- -0.08
- Fwd P/E
- 0.68
- PEG
- -0.01
- P/S
- 7.44
- P/B
- 0.09
- EV/EBITDA
- -0.24
- Div Yield
- 0.00%
- Gross Margin
- 30.73%
- Op Margin
- -1671.08%
- Net Margin
- -4620.92%
- ROE
- -53.51%
- ROIC
- -15.19%
Latest fiscal year · YoY change
- Revenue
- $431.61K+215.9%
- Gross Profit
- $331.48K+5420.1%
- Op Income
- $-16,244,792
- Net Income
- $-41,512,264-557.9%
- EPS
- $-67.50-200.4%
- OCF Growth
- +6.2%
- FCF Growth
- +6.3%
- 52W High
- $65.00
- 52W Low
- $3.23
- 50D MA
- $8.98
- 200D MA
- $10.12
- Beta
- 3.98
- RSI (14)
- 11
- Avg Volume
- 223.65K
No earnings-call transcripts are available for SCNX yet.
- Free Float
- 76.1%
- Shares Outstanding
- 1.63M
- Float Shares
- 1.24M
of shares held by institutions
14 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 606.15K | ▲ 449.13K |
| Vanguard Capital Management LLC | 510.39K | ▲ 102.30K |
| Geode Capital Management, LLC | 334.97K | ▼ 97.22K |
| Susquehanna International Group, Llp | 235.12K | ▲ 235.12K |
| Vanguard Fiduciary Trust Co | 198.06K | 0 |
| Citadel Advisors LLC | 164.85K | ▲ 164.85K |
| Hrt Financial LP | 132.67K | ▲ 132.67K |
| Xtx Topco Ltd | 104.80K | ▲ 57.12K |
| Northern Trust Corp | 87.61K | ▲ 73.71K |
| Ubs Group AG | 85.92K | ▼ 21.92K |
| Jane Street Group, LLC | 75.73K | ▲ 48.09K |
| Virtu Financial LLC | 47.55K | ▼ 36.66K |
Held by 19 ETFs
Biggest fund positions in SCNX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 25 | Sherb Eric Michael | other | 50,000 |
| Dec 31, 25 | Sherb Eric Michael | other | 0 |
| Mar 13, 25 | Sherb Eric Michael | other | 0 |
| Feb 20, 26 | Shankar Hariharan | other | 500,000 |
| Oct 1, 25 | Shankar Hariharan | other | 300,000 |
| Apr 14, 25 | Shankar Hariharan | other | 750,000 |
| Sep 19, 24 | Shankar Hariharan | other | 1,916,816 |
| Mar 10, 25 | Shankar Hariharan | other | 30,000 |
| Sep 19, 24 | Shankar Hariharan | other | 356,480 |
| Sep 19, 24 | Shankar Hariharan | other | 356,480 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SCNX coverage
Recent articles, reports, and earnings notes.
No research on SCNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SCNX report →SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
globenewswire.com · Oct 2
Scienture Holdings, Inc. Announces Reverse Stock Split
globenewswire.com · Sep 30
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
globenewswire.com · Sep 22
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
globenewswire.com · Sep 9
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
globenewswire.com · Aug 14
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
globenewswire.com · Aug 12
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
globenewswire.com · Jul 9
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
globenewswire.com · Jul 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.